

In Vivo Occupancy of D₂ Dopamine Receptors by Nafadotride

Beth Levant, Ph.D., and Nichole R. Vansell, B.A.

Nafadotride has been proposed as a selective antagonist for the D₃ dopamine receptor. This drug has been shown to exhibit selectivity between D₂ and D₃ dopamine receptors in in vitro assay systems; however, the in vivo D₂/D₃ selectivity of the compound has not been determined. In this study, protection against inactivation by EEDQ was used as a measure of in vivo occupancy of D₂ receptors by behaviorally relevant doses of nafadotride (0.1–10 mg/kg, SC and IP) in adult, male Sprague-Dawley rats. Ex vivo [³H]spiperone binding was then determined in striatal

membranes. l-Nafadotride (10 mg/kg) protected 71% of D₂ receptors after SC administration; 40% after IP administration. Protection of 13% of D₂ receptors was observed at a dose of 3 mg/kg (SC). These data suggest that blockade of D₂ receptors contributes to the pharmacological effects of nafadotride when administered at doses above 1 mg/kg (SC) or 3 mg/kg (IP).

[Neuropsychopharmacology 17:67–71, 1997] © 1997 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

KEY WORDS: *Nafadotride; [³H]Spiperone; EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline); D₂ dopamine receptor; Striatum; In vivo occupancy*

Numerous pharmacological studies have been performed to date with the aim of elucidating the function(s) of the D₃ dopamine receptor. A member of the family of D₂-like receptors, the D₃ subtype is of particular interest, because its mRNA is expressed preferentially in brain regions such as the nucleus accumbens, olfactory tubercle, and islands of Calleja (Bouthenet et al. 1991; Sokoloff et al. 1990). These brain regions are terminal fields of the mesolimbic dopamine projection, which is hypothesized to be involved in producing psychotic symptoms in schizophrenia. Unlike mRNA for the D₂ receptor, D₃ mRNA is expressed in low density in the caudate/putamen (Bouthenet et al. 1991; Sokoloff et al. 1990). This suggests that the D₃ receptor may be a

target for novel antipsychotic drugs that might be free of the extrapyramidal effects.

Until recently, the utility of pharmacological approaches to studying this novel receptor in vivo has been limited by availability of selective compounds. D₃-selective agonists, such as 7-OH-DPAT, have been identified. Numerous studies using these drugs have suggested possible involvement of the site in a variety of behaviors, including the modulation of locomotor activity and the reinforcing properties of cocaine (Daly and Waddington 1993; Caine and Koob 1993; McElroy et al. 1993). A D₃-selective antagonist, nafadotride, has recently been identified (Sautel et al. 1995). This drug exhibits roughly 10-fold higher affinity for D₃ receptors over D₂ in in vitro binding studies in transfected cell lines and produces effects consistent with antagonist activity at dopamine receptors in a variety of in vitro and in vivo assays. Initial studies of the behavioral effects of nafadotride in the rat also indicate the involvement of the D₃ site in the modulation of locomotor activity and further suggest the utility of this compound in the study of D₃-mediated effects.

To adequately interpret the effects of systemically administered drug in terms of activity at specific recep-

From the Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.

Address correspondence to: Beth Levant, Ph.D., Department of Pharmacology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7417.

Received December 9, 1996; accepted January 31, 1997.

tors, it is essential to determine the sites with which that compound interacts *in vivo* as well as *in vitro*. This study uses protection from inactivation by the alkylating agent *N*-ethoxycarbonyl-2-ethoxy-1,2 dihydroquinoline (EEDQ) as a measure of receptor occupancy. This type of assessment has been employed to determine *in vivo* occupancy of D₂ receptors by antipsychotic drugs (Meller et al. 1985; Nowak et al. 1989; Saller et al. 1989; Matsubara et al. 1993). We have previously used a modification of this approach to assess the occupancy of D₂ receptors by the D₃-selective dopamine agonist 7-OH-DPAT (Levant et al. 1996). This method will now be used to determine the occupancy of D₂ sites after the administration of behaviorally relevant doses of the D₃-selective dopamine antagonist nafadotride. Although it would be desirable to simultaneously assess D₃ receptor occupancy in animals treated with nafadotride, we have found the D₃ site to be insensitive to inactivation by EEDQ (Levant 1995). Hence, the scope of the present study is limited to the D₂ receptor.

MATERIALS AND METHODS

Experimental Procedure

All experiments were carried out in accordance with the declaration of Helsinki and the NIH Guide for the Care and Use of Laboratory Animals. Adult, male, Sprague-Dawley rats (200–300 g; Harlan Labs, Indianapolis, IN) were housed three to a cage with free access to laboratory diet and water. The animal facility was temperature controlled and maintained on a 12-h light/dark cycle. Animals were obtained at least 5 days before experiments and were accustomed to handling.

Groups of four to five rats were pretreated with either nafadotride, haloperidol, or the respective vehicle before treatment with EEDQ. *l*-Nafadotride (0.1–10 mg/kg, SC or IP; Bioprojet, Paris) was administered in 0.9% saline 20 min before treatment with EEDQ. The pretreatment interval was determined on the basis of the detection of overt behavioral effects in preliminary studies. Haloperidol (1 mg/kg, IP; RBI, Natick, MA) was administered in 0.3% tartaric acid 1 h before EEDQ. The dose of EEDQ (Aldrich, Milwaukee, WI) was 10 mg/kg (SC) administered in 50% ethanol. All drugs were administered in a volume of 1 ml/kg. Three hours after treatment with EEDQ, rats were killed by decapitation. Brains were rapidly removed, frozen on dry ice, and stored at –70°C until assayed.

[³H]Spiperone Binding Assays

[³H]Spiperone binding was performed in membranes prepared from caudate/putamen as previously described (Seeman et al. 1985). Striatal tissue was dissected from each brain and homogenized in 20 vol (w/v)

of buffer (50 mmol/L Tris-HCl, 5 mmol/L KCl, 2 mmol/L MgCl₂, and 2 mmol/L CaCl₂; pH 7.4 at 23°C) using a PRO homogenizer (setting 4 for 10 s). The crude homogenate was centrifuged twice (15 min at 48,000 × *g*), resuspending the pellet each time in 20 vol of buffer. The final pellet was resuspended in buffer to yield a final tissue concentration of 1.5 mg original wet weight/ml. Binding assays were performed in duplicate in polystyrene tubes in a final volume of 0.5 ml. The final concentration of [³H]spiperone (24 Ci/mmol; Amersham, Arlington Heights, IL) was ~100 pmol/L. Nonspecific binding was defined in the presence of 1 μmol/L (+)-butaclamol (RBI, Natick, MA). Binding was initiated by the addition of membrane homogenate. Tubes were incubated for 2 h at 23°C. The reaction was terminated by rapid filtration through Whatman GF/B filters using a Brandel cell harvester. Filters were washed 3 times with 3 ml ice-cold buffer (50 mmol/L Tris, pH 7.4 at 23°C), and placed in scintillation vials. After the addition of Beckman Ready Protein+ cocktail, vials were shaken, allowed to equilibrate for 2 h, and counted on a Beckman 6500 scintillation counter. Protein concentrations were determined using the BCA method (Pierce, Rockford, IL). Specific [³H]spiperone binding is expressed as fmol/mg protein.

Data Analysis

Receptor protection was calculated from data from the three experimental conditions using the following equation: percent protection = [(drug + EEDQ) – (vehicle + EEDQ)]/[(vehicle + vehicle) – (vehicle + EEDQ)]. Data were analyzed for statistically significant effects by ANOVA followed by Dunnett's test or the Student-Newman-Keuls multiple comparison's test as appropriate. Significance was assumed at *p* < .05.

RESULTS

The ability of the nafadotride to protect D₂ receptors from inactivation by EEDQ was assessed. In preliminary studies *l*-nafadotride (10 mg/kg, SC) produced an inhibition of locomotor activity within 20 min of administration, which persisted for a period of approximately 3 h (data not shown). Because of this relatively short duration of action, a post-EEDQ treatment interval of 3 h was selected for these experiments.

For initial studies, four treatment groups were included in these experiments: vehicle + vehicle (control), drug + vehicle, drug + EEDQ, and vehicle + EEDQ (Figure 1). *l*-Nafadotride (10 mg/kg, IP) produced significant protection of [³H]spiperone binding sites from inactivation by EEDQ. The amount of [³H]spiperone binding detected in animals treated with this dose of *l*-nafadotride followed by vehicle was not significantly




Figure 1. Effects of *l*-nafadotride and EEDQ on ex vivo [³H]spiperone binding and protection of receptors by haloperidol. Rats were pretreated with *l*-nafadotride (10 mg/kg, IP); haloperidol (1 mg/kg, IP) or vehicle before injection with EEDQ (10 mg/kg, SC) or vehicle. Rats were killed 3 h after injection with EEDQ. Striatal membranes were incubated with ~100 pmol/L [³H]spiperone at 23°C for 2 h. Nonspecific binding was defined by 1 μM (+)-butaclamol. Data represent the mean ± SEM (*n* = 4–5 animals/group). **p* < .01 vs. control (vehicle + vehicle), †*p* < .01 vs. vehicle + EEDQ by ANOVA and the Student-Newman-Keuls multiple comparisons test.

different from control. This indicates that brain membranes were washed sufficiently to remove any potentially interfering drug before the binding assay. As such, a drug + vehicle treatment group was not included in subsequent experiments. As an additional control, a group of animals was pretreated with haloperidol (1 mg/kg, IP) 1 h before EEDQ. In agreement with previous studies using 4-h and 24-h post-EEDQ intervals (Saller et al. 1989; Levant et al. 1996), haloperidol administration resulted in 57% occupancy of [³H]spiperone labeled sites.

Pretreatment with nafadotride resulted in dose-related protection of [³H]spiperone binding sites (Figure 2). *l*-Nafadotride (10 mg/kg) protected 71% of D₂ receptors after subcutaneous administration. Intraperitoneal administration of the drug (10 mg/kg) protected 40% of [³H]spiperone-labeled sites. Subcutaneous administration of *l*-nafadotride (3 mg/kg) protected 13% of D₂ receptors but failed to reach statistical significance. Negligible protection was observed after administration of *l*-nafadotride at doses below 3 mg/kg (SC) or 10 mg/kg (IP).

DISCUSSION

Initial studies with nafadotride indicate that this putatively D₃-selective antagonist produces differential behavioral effects when administered at low or high doses. For example, in rats, low doses of the drug appear to stimulate locomotor activity, whereas higher doses inhibit locomotion (Sautel et al. 1995). Based on these observations, and those of the effects of D₃-selective agonists, it has been proposed that blockade of D₃ receptors may underlie the stimulatory effects of low doses of nafadotride, whereas the inhibition in locomotor activity, observed at higher doses, results from the

nonselective actions of the drug at D₂ receptors. This hypothesis is concordant with the 10-fold D₃/D₂ selectivity reported for the drug in vitro (Sautel et al. 1995). The D₃/D₂ selectivity of the drug in vivo, however, had not been determined. To adequately interpret the effects of systemically administered nafadotride in terms




Figure 2. Protection of [³H]spiperone binding sites by *l*-nafadotride. Rats were pretreated with various doses of *l*-nafadotride (0.1–10 mg/kg, SC or IP) or vehicle 20 min before injection with EEDQ (10 mg/kg, SC). Rats were killed 3 h after injection with EEDQ. Striatal membranes were incubated with ~100 pmol/L [³H]spiperone at 23°C for 2 h. Nonspecific binding was defined by 1 μmol/L (+)-butaclamol. Data are expressed as percent protection calculated for each independent experiment as described in Materials and Methods. Data shown represent the mean ± SEM (*n* = 4–5 animals/group). **p* < .01 vs. vehicle + EEDQ by ANOVA and Dunnett's test.

of receptor interactions, the selectivity of the compound must be determined *in vivo* as well as *in vitro*. The present data provide direct evidence of interactions of nafadotride with D₂ receptors *in vivo*.

This study used [³H]spiperone binding in striatal membranes to assess the density of D₂ dopamine receptors. Although there is some dispute in the literature regarding the D₂/D₃ selectivity of spiperone, our lab and others have reported significantly higher affinity for this drug at D₂ receptors than D₃ (Sokoloff et al. 1990; Levant and De Souza 1993; Levant et al. 1995). Because there are relatively few D₃ or D₄ receptors in the striatum (for review, see Levant 1996), the contribution of these sites to the [³H]spiperone binding observed in this study is negligible. Thus, the data represent a reasonable assessment of the occupancy of non-D₃, D₂-like receptors and a rational estimate of D₂ receptor occupancy.

The D₃ antagonist *l*-nafadotride produced significant protection of D₂ receptors from inactivation by EEDQ at a dose of 10 mg/kg. Somewhat greater protection of D₂ receptors was observed after subcutaneous administration of the drug than intraperitoneal injection. This difference is most likely due to more extensive first-pass metabolism of the drug after intraperitoneal administration. It has been previously demonstrated that less than 20% receptor occupancy is required for the blockade of dopamine agonist-induced behaviors by D₂ receptor antagonists (Schotte et al. 1993). As such, when administered at a dose of 10 mg/kg, blockade of D₂ receptors is likely to contribute the effects of nafadotride such as catalepsy and decreased locomotor activity (Sautel et al. 1995). Protection of 13% of D₂ sites was observed after treatment with a dose of 3 mg/kg (SC). Whereas this dose did not produce a statistically significant effect, it is likely that effects produced by nafadotride at this dose may also result from the antagonism of the D₂ receptor.

In contrast, negligible D₂ receptor protection was observed after the administration of *l*-nafadotride at the behaviorally active doses of 3 mg/kg (IP) or 1 mg/kg (SC) and below. Although the present data do not directly demonstrate interactions of nafadotride with the D₃ receptor, the findings suggest that the pharmacological effects of these doses of the drug, such as increased locomotor activity (Sautel et al. 1995), may well result from the blockade of these sites. Blockade of the D₃ site may also contribute to catalepsy in a small percentage of animals as well as enhancing the reinforcing properties of food (Sautel et al. 1995; Chaperon and Thiebot 1996). However, there are several limitations on the interpretation of these observations. First, although nafadotride exhibited very low potency at a variety of non-dopaminergic receptors *in vitro* (Sautel et al. 1995), these findings cannot eliminate the possible activity of the drug at receptors other than D₂ *in vivo*. Second, the

interpretation of the literature in the context of the present data is limited to those studies utilizing subcutaneous or intraperitoneal administration in the rat. Because of pharmacokinetic factors such as absorption and metabolism, these data may not apply to comparable doses administered by other routes or in other species. Third, the present study was limited to the study of striatal membranes. As such, the data may not necessarily reflect D₂ receptor occupancy in other brain regions. Finally, the present data cannot differentiate between protection of D₂ receptors by nafadotride or by an active metabolite(s).

In summary, the present data demonstrate that systemically administered nafadotride produces dose-dependent protection of D₂ dopamine receptors from inactivation by EEDQ. Significant protection of these sites is observed at a dose 10 mg/kg when administered by subcutaneous or intraperitoneal routes. These findings support the interpretation of the biphasic behavioral effects produced by nafadotride (Sautel et al. 1995) and indicate the utility of this drug for further study of the functional role of the D₃ receptor.

ACKNOWLEDGMENTS

The authors thank Kimberly A. Morgan for technical assistance in this project and are grateful to Dr. Pierre Sokoloff of INSERM and Dr. Yves Joulin of Bioprojet for the generous donation of nafadotride. This work was supported by NIMH MH 52839.

REFERENCES

- Bouthenet M-L, Souil E, Martres M-P, Sokoloff P, Giros B, Schwartz J-C (1991): Localization of dopamine D₃ receptor mRNA in the rat brain using *in situ* hybridization histochemistry: Comparison with dopamine D₂ receptor mRNA. *Brain Res* 564:203–219
- Caine SB, Koob GF (1993): Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. *Science* 260:1814–1816
- Chaperon F, Thiebot MH (1996): Effects of dopaminergic D₃ receptor preferring ligands on the acquisition of place conditioning in rats. *Behav Pharmacol* 7:105–109
- Daly SA, Waddington JL (1993): Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. *Neuropharmacology* 32:509–510
- Levant B (1995): Differential sensitivity of [³H]7-OH-DPAT-labeled binding sites in rat brain to inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. *Brain Res* 698:146–154
- Levant B (1996): Distribution of dopamine receptor subtypes in the CNS. In Stone TW (ed), *CNS Neurotransmitters and Neuromodulators*. Dopamine. Boca Raton, FL, CRC Press, pp 77–87

- Levant B, De Souza EB (1993): Differential pharmacological profile of striatal and cerebellar dopamine receptors labeled by [³H]quinpirole: identification of a discrete population of D₃ receptors. *Synapse* 14:90–95
- Levant B, Grigoriadis DE, De Souza EB (1995): Relative affinities of dopaminergic drugs at D₂ and D₃ dopamine receptors. *Eur J Pharmacol* 278:243–247
- Levant B, Bancroft GN, Selkirk CM (1996): In vivo occupancy of D₂ dopamine receptors by 7-OH-DPAT. *Synapse* 24:60–64
- Matsubara S, Matsubara R, Kusumi I, Koyama T, Yamashita I (1993): Dopamine D₁, D₂ and serotonin₂ receptor occupation by typical and atypical antipsychotic drugs in vivo. *J Pharmacol Exp Ther* 265:498–508
- McElroy J, Zeller KL, Amy KA, Ward KA, Cawley JF, Mazzola AL, Keim W, Rohrbach K (1993): In vivo agonist properties of 7-hydroxy-N,N-Di-N-propyl-2-aminotetralin, a dopamine D₃-selective receptor ligand. *Drug Dev Res* 30:257–259
- Meller E, Bohmker K, Goldstein M, Friedhoff AJ (1985): Inactivation of D₁ and D₂ dopamine receptors by N-ethoxycarbonyl-2-ethoxy-dihydroquinoline in vivo: Selective protection by neuroleptics. *J Pharmacol Exp Ther* 233:656–662
- Nowak G, Arnt J, Hyttel J (1989): EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors. *Eur J Pharmacol* 153:309–311
- Saller CF, Kreamer LD, Adamovage LA, Salama AI (1989): Dopamine receptor occupancy in vivo: Measurement using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). *Life Sci* 45:917–929
- Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A, Wermuth CG (1995): Nafadotride, a potent preferential dopamine D₃ receptor antagonist, activates locomotion in rodents. *J Pharmacol Exp Ther* 275:1239–1246
- Schotte A, Janssen PFM, Megens AAHP, Leysen JE (1993): Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. *Brain Res* 631:191–202
- Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990): Molecular cloning and characterization of a novel dopamine receptor (D₃) as a target for neuroleptics. *Nature* 347:146–151